Torrent Pharmaceuticals gets 'Hold' rating, consolidation phase almost over: Edelweiss

Dec 30 2013, 10:14 IST
Comments 0
SummaryAggressive M&A valuations to strain ROCE

Torrent Pharmaceuticals Ltd (TRP) has acquired Elder Pharma’s India business (sales of R4 bn and 35% Ebitda margin) for Rs 20 bn. The deal valued at 4.8 times EV/sales and 14x EV/Ebitda (enterprise value/earnings before interest, taxes, depreciation, and amortisation), gives TRP a ready brand portfolio to aggressively entrench in new focus specialties of women care, pain management and nutraceuticals.


While the acquired portfolio is complementary and synergistic, it is likely to result in earnings cut of 11% and 14% for FY14e (estimates) and FY15e, respectively, add leverage of 1.2 times from zero net debt and hit RoCEs (returns on capital employed) of TRP. Ergo, we downgrade to ‘Hold’ and believe TRP will have to harness strong execution capability to scale up the acquired portfolio to currently generated returns level.

Acquisition offers deep synergies and established brands: Elder’s specialty portfolio offers multiple synergies to TRP such as addition of leading brands—Shelcal, Chymoral, Carnisure—strengthening its presence in gynecology, pain and vitamin segments. It also renders deeper access to tier II-IV markets with 1,100 market representatives and adds distribution network of 2,900 stockists to its existing base of 1,700, thereby enabling better penetration in North and West India. However, we believe it comes at a dearer value (five times sales) with projected payback of over ten years and additional strain on balance sheet, limiting future expansion capacity.

Strong scale up potential, but earnings accretion could be delayed: Elder sales have declined sharply due to lack of product supplies in market. Thus, we perceive strong scale up potential with leveraging of key brands such as Shelcal to Torrent’s existing portfolio. However, TRP will have to scale up Ebitda of the acquired business over two times (R3 bn from R1.5 bn) to make it earnings accretive by FY15e.

Outlook and valuations: execution critical: Though we are positive on the acquired product portfolio, we expect it to be dilutive to business RoCE. Currently, TRP’s overall business generates more than 40% RoCE; however, the acquisition yields less than 10% RoCE. Ergo, the company will have to increase profitability four-five times to achieve the level of returns generated historically. Moreover, we believe execution risk is higher as it is TRP’s first large buyout with no historical precedence, suggesting integration and turnout capability of management. Hence, we do not expect significant upside to current valuations and downgrade to ‘Hold /Sector Performer’ rating. At,

Single Page Format
Ads by Google
Reader´s Comments
| Post a Comment
Please Wait while comments are loading...